2. Academic Validation
  3. Targeting RNA Polymerase I Inhibits Ribosome Biogenesis to Block Liver Fibrosis Progression

Targeting RNA Polymerase I Inhibits Ribosome Biogenesis to Block Liver Fibrosis Progression

  • Liver Int. 2026 Jan;46(1):e70478. doi: 10.1111/liv.70478.
Wei Luo 1 2,  Lixian Yi 3,  Yu Zhang 1 2,  Jing Zhou 1 2,  Shihui Li 1 2,  Fatma A Abouelnazar 4,  Yanjin Wang 4,  Yongmin Yan 1 2 3
Affiliations

Affiliations

  • 1 Changzhou Key Laboratory of Exosome Basics and Translational Applications, Wujin Hospital Affiliated With Jiangsu University, Changzhou, China.
  • 2 Wujin Institute of Molecular Diagnostics and Precision Cancer Medicine of Jiangsu University, Changzhou, China.
  • 3 Department of Medical Technology, Suzhou Vocational Health College, Suzhou, Jiangsu, China.
  • 4 Department of Laboratory Medicine, Wujin Hospital Affiliated With Jiangsu University (Wujin Clinical College of Xuzhou Medical University), Changzhou, China.
PMID: 41388799 DOI: 10.1111/liv.70478
Abstract

Background & aims: Liver fibrosis significantly burdens global health, and increased protein synthesis during hepatic stellate cell (HSC) activation plays a crucial role in its progression. Ribosome is the site of protein synthesis. RNA polymerase I (Pol I) is a protein that regulates the transcription of ribosomal DNA (rDNA) genes into ribosomal RNA (rRNA) in ribosomal biogenesis. Therefore, we investigated the role and mechanism of Pol I-regulated ribosome biogenesis in HSCs activation and liver fibrosis progression.

Methods: Initially, we assessed the expression levels of Pol I in the serum of patients diagnosed with liver fibrosis. Then, we assessed Pol I-regulated ribosome biogenesis levels in mouse models of metabolic dysfunction-associated steatohepatitis (MASH) and carbon tetrachloride (CCl4). Finally, we employed overexpression or knockdown of the Pol I gene in LX2 cells or utilised the Pol I inhibitor CX-5461 in vivo and in vitro, assessing the levels of ribosome biogenesis and HSCs activation.

Results: Pol I levels were elevated in the serum of patients with liver fibrosis. Additionally, Pol I-regulated ribosome biogenesis levels were significantly increased in both MASH and CCl4 mouse models, as well as in HSCs activated by transforming growth factor beta 1 (TGFβ1). The overexpression of Pol I was found to enhance the activation of HSCs and promote ribosome biogenesis, while the knockdown of Pol I or the inhibitor CX-5461 inhibited these processes.

Conclusions: Pol I-regulated ribosome biogenesis is significantly increased during HSCs activation and liver fibrosis progression. Pol I may serve as a potential target for the diagnosis and treatment of liver fibrosis.

Keywords

HSC activation; liver fibrosis; pol I; rRNA; ribosome biogenesis.

Figures
Products
Inhibitors & Agonists
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-12484
    98.56%, DNA Intercalator/Pol I Elongation Inhibitor
Other Products